Evidence map›Paper›PMID 42818103›Full record

ArticlemedRxiv : the preprint server for health sciences2026

MES: A Multi-Agent Evidence Synthesis System for Medical Decision-Making.

Haoyang Li, Weishen Pan, Suraj Rajendran, Chengxi Zang, Judy Gabeskiria, Valencia Liu, Vivian Feng, Mahitha Penmetsa, Lydia Lin, Atindra Bhalchandra Jayakar and 4 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Haoyang LiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-3544-5563
Weishen PanDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Suraj RajendranTri-Institutional Computational Biology & Medicine Program, Cornell University, New York, NY, USA.ORCID 0000-0002-8149-0157
Chengxi ZangDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Judy GabeskiriaWeill Cornell Medicine, New York, NY, USA.
Valencia LiuCornell AI Innovation Hub, Cornell University, Ithaca, NY, USA.
Vivian FengCornell AI Innovation Hub, Cornell University, Ithaca, NY, USA.
Mahitha PenmetsaCornell AI Innovation Hub, Cornell University, Ithaca, NY, USA.
Lydia LinCornell AI Innovation Hub, Cornell University, Ithaca, NY, USA.
Atindra Bhalchandra JayakarCornell AI Innovation Hub, Cornell University, Ithaca, NY, USA.
Ayham BoucherCornell AI Innovation Hub, Cornell University, Ithaca, NY, USA.
Edward J SchenckDivision of Pulmonary and Critical Care Medicine, Department of Medicine, New York-Presbyterian Hospital-Weill Cornell Medical Center, Weill Cornell Medicine, New York, NY, USA.
He S YangDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Fei WangDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.

Funding

TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimer’s DiseaseR01AG076448 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng, Li Gan · 2022 to 2026
$4.0M
Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical KnowledgeR01AG076234 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jiang Bian, Fei Wang · 2022 to 2026
$3.8M
Eligibility criteria design for Alzheimer's trials with real-world data and explainable AIR01AG080991 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Jiang Bian, Fei Wang · 2023 to 2026
$3.1M
Disparities of Alzheimer's disease progression in Sexual Minority IndividualsR01AG080624 · NIA · UNIVERSITY OF FLORIDA · PI Jiang Bian, Yi Guo · 2023 to 2026
$3.1M
Identification of Mild Cognitive Impairment using Machine Learning from Language and Behavior MarkersRF1AG072449 · NIA · MICHIGAN STATE UNIVERSITY · PI DODGE, HIROKO HAYAMA, WANG, FEI · 2021 to 2023
$2.6M
Post-Acute Sequelae of SARS-CoV-2 Infection and Subsequent Disease Progression in Individuals with AD/ADRD: Influence of the Social and Environmental Determinants of HealthRF1AG084178 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BIAN, JIANG, HU, HUI · 2023 to 2023
$2.6M
Progression Subtyping and Drug Target Identification for Parkinson's Disease with Integrative Machine LearningR01NS140142 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Chang Su · 2025 to 2026
$1.3M
NIA NIH HHS R01 AG076234NIA NIH HHS R01 AG076448NIA NIH HHS R01 AG080624NIA NIH HHS R01 AG080991NIA NIH HHS RF1 AG072449NIA NIH HHS RF1 AG084178NINDS NIH HHS R01 NS140142
6 · The paper itself

Abstract

Medical evidence synthesis increasingly requires published studies, real-world clinical data and structured biomedical knowledge, yet most automated systems remain centered on literature retrieval and summarization. Here we present MES, a multi-agent framework for source-grounded medical evidence synthesis. MES coordinates six specialized agents to decompose clinical questions, retrieve literature and trial evidence, generate question-specific RWE by constructing and analyzing real-world cohorts, query biomedical knowledge graphs, integrate quantitative findings and screen generated claims against their cited evidence. The framework uses evidence-based medicine taxonomies to clarify underspecified questions, adapts evidence use when sources are absent or discordant and reports unresolved gaps rather than forcing consensus. MES also provides claim-level provenance tracking and cross-agent consistency checking, allowing final reports to distinguish trial evidence, real-world associations and knowledge-graph support. We evaluated MES in two clinical use cases and across 144 clinical queries spanning six evidence-based medicine categories. MES generated structured reports that preserved source traceability, identified cross-source disagreement and communicated uncertainty across diverse clinical question types. MES provides an auditable framework for organizing, testing and contextualizing heterogeneous clinical evidence while keeping the evidentiary basis of each conclusion explicit.

Identifiers

PMID42818103
PMCPMC13622301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.